Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03626701
Other study ID # CTP006-2
Secondary ID RESTORE KIDS
Status Terminated
Phase N/A
First received
Last updated
Start date March 3, 2020
Est. completion date June 3, 2022

Study information

Verified date May 2023
Source Avita Medical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date June 3, 2022
Est. primary completion date June 23, 2021
Accepts healthy volunteers No
Gender All
Age group 1 Year to 16 Years
Eligibility Inclusion Criteria: 1. Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury. 2. The patient has a thermal burn injury that is: 1. = 30% TBSA (exclusive of superficial areas) and 2. = 10% of the burn injury TBSA is a full-thickness burn. 3. The Index Burn must be a clean partial-thickness burn injury > or = to 160 cm2 and between 2-20% BSA (inclusive). 4. The Index Burn may not cover the face, hand, foot or perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas). 5. The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule. 6. The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary. 7. The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. 8. In the opinion of the investigator, the patient and/or parent/guardian must be able to: 1. Understand the full nature and purpose of the study, including possible risks and adverse events, 2. Understand instruction, and 3. Provide voluntary informed written consent/assent as appropriate for study participation. Exclusion Criteria: 1. Not able to understand English or Spanish. 2. Burns caused by chemicals, electricity or radiation. 3. Patients presenting with only 3rd-degree/full-thickness wounds which require immediate autografting. 4. Burn injury has had prior treatment for definitive closure. 5. Patients for whom use of sedation/general anesthesia is not medically appropriate. 6. Superficial/trivial burns or burns that in the investigator's opinion appear to be healing sufficiently such that care under this protocol would be inappropriate. 7. Patient requires immediate or staged surgical procedures for closure of their partial-thickness burns. 8. Conditions, e.g., previous burn injury to study area, poor nutritional status, poorly controlled diabetes mellitus (HbA1c >9%), that in the investigator's opinion may compromise subject safety or trial objectives. 9. Current use of medications, e.g., immunosuppressive agents (excluding inhaled corticosteroids), that in the investigator's opinion may compromise subject safety or trial objectives. 10. Inhalation injury. 11. Active infection, cellulitis or need for immediate grafting at the planned treatment areas. 12. Concerns for parent/guardian's ability to provide appropriate follow-up care. 13. Subjects with a known hypersensitivity to trypsin or compound sodium lactate for irrigation solution. 14. Subjects with a known sensitivity to silver. 15. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements). 16. Immediate life-threatening condition or life expectancy less than one year. 17. Previous randomization within this investigation. Post-Randomization Inclusion Criteria (prior to treatment): 1. Patient randomized (and will be treated) within 72 hours from the time of the burn injury. 2. Patient continues to meet all pre-randomization inclusion criteria. Post-Randomization Exclusion Criteria (prior to treatment): 1. Incidental finding of any pre-randomization exclusion criteria. Consented subjects who do not meet the post-randomization eligibility criteria and did not receive study treatment will be followed through the Day 28 visit and then withdrawn from the study. The criteria for which exclusion was based will be documented.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
Combination Product:
Mepilex® Ag Wound Dressing
Application of Mepilex® Ag Wound Dressing
Procedure:
Conventional autografting (only when indicated)
When indicated, conventional autografting in accordance with Investigator's standard practice

Locations

Country Name City State
United States University of North Carolina Chapel Hill North Carolina
United States Medical University of South Carolina Charleston South Carolina
United States University Medical Center New Orleans New Orleans Louisiana
United States Saint Christopher's Hospital for Children Philadelphia Pennsylvania
United States Arizona Burn Center / Valleywise Health Phoenix Arizona
United States Evan Hayes Burn Center, Virginia Commonwealth University Richmond Virginia
United States University of Washington Regional Burn Center at Harborview Medical Center Seattle Washington
United States University of South Florida Tampa General Hospital Tampa Florida
United States Wake Forest Baptist Medical Center Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Avita Medical Biomedical Advanced Research and Development Authority

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Index Burns With Day 10 Healing Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28 10 Days post-treatment
Secondary Incidence of Day 21 Healing of the Index Burn Incidence of Day 21 healing of the Index Burn confirmed on Day 28 Day 21, confirmed on Day 28
Secondary Incidence of Conventional Autografting to Achieve Healing of the Index Burn Incidence of conventional autografting to achieve healing of the Index Burn Through Day 28
See also
  Status Clinical Trial Phase
Completed NCT05023135 - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed NCT05276869 - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Not yet recruiting NCT06076031 - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing N/A
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Recruiting NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT03159182 - Study of Silicone Material Inserts To Treat Burn Scars N/A
Recruiting NCT02904941 - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns N/A
Completed NCT02681757 - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01437852 - StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns Phase 1
Completed NCT01214811 - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Phase 3
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Terminated NCT00634166 - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group Phase 4
Terminated NCT00824681 - Effect of Music Therapy on Families of Burn Patients Phase 1
Terminated NCT00464386 - Continuous Glucose Monitoring (POC) in the ICU N/A
Withdrawn NCT00216983 - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding N/A